A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 19, 2023

Primary Completion Date

October 14, 2024

Study Completion Date

October 25, 2024

Conditions
Immunoglobulin A Nephropathy
Interventions
DRUG

Sparsentan

Target dose of 400 mg daily

Trial Locations (30)

10013

Travere Investigational Site, New York

11365

Travere Investigational Site, Fresh Meadows

12065

Travere Investigation SIte, Clifton Park

19104

Travere Investigational Site, Philadelphia

28546

Travere Investigational Site, Jacksonville

28562

Travere Investigational Site, New Bern

29203

Travere Investigational Site, Columbia

35233

Travere Investigational Site, Birmingham

40205

Travere Investigational Site, Louisville

43210

Travere Investigational Site, Columbus

46804

Travere Investigational Site, Fort Wayne

60611

Travere Investigational Site, Chicago

60805

Travere Investigational Site, Evergreen Park

66160

Travere Investigational Site, Kansas City

71101

Travere Investigational Site, Shreveport

75230

Travere Investigational Site, Dallas

75246

Travere Investigational Site, Dallas

80230

Travere Investigational Site, Denver

83202

Travere Investigational Site, Chubbuck

83404

Travere Investigational Site, Idaho Falls

83706

Travere Investigational Site, Boise

87109

Travere Investigational Site, Albuquerque

91206

Travere Investigational Site, Glendale

91910

Travere Investigational Site, Chula Vista

92844

Travere Investigational Site, Garden Grove

Unknown

Travere Investigational Site, Hong Kong

Travere Investigational Site, Kowloon

Travere Investigational Site, Shatin

Travere Investigational Site, Sheung Wan

Travere Investigational Site, Tsuen Wan

All Listed Sponsors
lead

Travere Therapeutics, Inc.

INDUSTRY

NCT05856760 - A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN | Biotech Hunter | Biotech Hunter